<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509351</url>
  </required_header>
  <id_info>
    <org_study_id>POMCS</org_study_id>
    <nct_id>NCT02509351</nct_id>
  </id_info>
  <brief_title>Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section?</brief_title>
  <official_title>Randomized, Placebo-controlled Double Blind Study of Preoperative Misorostol for Reduction of Intraoperative Bleeding in Women Delivered by Ceserean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Misoprostol reduces the uterine bleeding after cesarean delivery without harmful effects
           on either mother or baby.

        -  The aim of the this study is to address if there is any benefits 'regarding the
           intra-operative blood loss' from preoperative rectal administration of 400 mic of
           Misoprostol in addition to the routinely administrated 10 units of oxytocin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question:

      In women undergoing elective ceserean section, is preoperative 400 mic Misoprostol reduce
      intra-operative blood loss?

      Research hypothesis:

      pre-operative Misoprostol doesn't reduce intraoperative blood loss in women undergoing
      ceserean section
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>volume of intraoperative blood loss</measure>
    <time_frame>30 minute</time_frame>
    <description>volume of intraoperative blood loss will be measured in &quot;cc&quot; by a didcated nurse who will use separate suction sets to differentiate between blood and liquor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maternal mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean measured blood loss</measure>
    <time_frame>1, 2, and 24 h postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>placental retention</measure>
    <time_frame>30 minutes</time_frame>
    <description>when the placenta is not delivered spontaneously for 30 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>requirement for blood transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>indicated per clinical protocol at the study site for mothers with a hemoglobin &lt;100 g/l and/or severe pallor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>requirement for additional management of PPH, including therapeutic uterotonic drugs or surgical or radiological procedures</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postpartum hemoglobin</measure>
    <time_frame>24 hours</time_frame>
    <description>less than 10gm%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean postpartum hematocrit</measure>
    <time_frame>24 hours</time_frame>
    <description>more than 10% drop in the postpartum hematocrit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women receiving pre-operative rectally administered 400 microgram misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placeboo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section</description>
    <arm_group_label>misoprostol</arm_group_label>
    <other_name>mesotac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placeboo</intervention_name>
    <description>women will recive 2 identical tablets as placeboo</description>
    <arm_group_label>placeboo</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  38-41 weeks of amenorrhea

          -  scheduled for elective lower segment cesarean section

        Exclusion Criteria:

          -  confirmed intrauterine fetal death

          -  more than previous 2 ceserean sections

          -  multiple pregnancy

          -  antepartum haemorrhage

          -  self-reported maternal heart disease

          -  current diagnosis of severe malaria or acute bacterial infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmy Dr metawe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed El Kotb Abdel Fattah</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

